Abstract
<h3>Objectives</h3> To evaluate the expression of CD30 protein in primary oral/oropharyngeal diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). <h3>Study Design</h3> DLBCL, NOS cases diagnosed from 2001 to 2020 were retrieved from pathology files. All cases had their diagnoses confirmed and CD30 expression evaluated by immunohistochemistry. Two cutoff values (>0% and >20%) were used to determine positivity for CD30 in each case. The results were descriptively reported, and statistical analyses were done when necessary. <h3>Results</h3> Fifty cases were retrieved and CD30 expression (>0%) was observed in 6 cases. However, 1 case was reclassified as Epstein-Barr virus–positive DLBCL, NOS and 1 case was reclassified as high-grade B-cell lymphoma. Forty-two DLBCL, NOS cases remained, and 4 cases were positive for CD30 (9.5%), with 2 cases demonstrating positivity in >20% of tumor cells. Three cases affected the oral cavity (7.3%) and 1 affected the oropharynx (9.0%). Three cases were classified as nongerminal center B cell type, all with a high proliferative index (>50%), and only 1 patient died during the follow-up period. <h3>Conclusions</h3> CD30 expression is uncommon in primary oral/oropharyngeal DLBCL, NOS, which may represent an obstacle for the use of brentuximab vedotin in the majority of these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
